Exelixis presented STELLAR‑303 phase III data showing that zanzalintinib plus atezolizumab reduced death risk by about 20% versus regorafenib in previously treated metastatic colorectal cancer, and the company plans an NDA filing before year‑end. Detailed results published in The Lancet and presented at ESMO showed a median overall survival improvement, but investors pushed shares down amid debate over magnitude and toxicity. Exelixis maintains it will file with regulators based on the totality of data.